Glucuronides in anti-cancer therapy.
Glucuronide prodrugs have shown promising efficacy in anti-cancer therapy due to their increased specificity and reduced systemic toxicity. The prodrugs can be used in prodrug monotherapy (PMT), which is based on elevated tumor beta-glucuronidase activity. beta-Glucuronidase activates the low-toxic prodrugs into highly cytotoxic agents specifically in the tumor site. The specificity of the prodrugs can be further improved by combined use with monoclonal antibodies against tumor-specific antigens, namely antibody-directed enzyme prodrug therapy (ADEPT); and the potency of the prodrugs can be greatly enhanced with the incorporation of an appropriate radionuclide in the combined chemo- and radio-therapy of cancer (CCRTC) strategy. The prodrugs can also be utilized to modify liposomes for efficient delivery of anti-cancer drugs.
Chen
Xi
X
Department of Chemistry, Wayne State University, Detroit, MI 48202, USA.
Wu
Bingyuan
B
Wang
Peng George
PG
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D015195:Drug Design; D005966:Glucuronidase / Q000378:metabolism; D020719:Glucuronides / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000628:therapy*; D011355:Prodrugs / Q000138:chemical synthesis* / Q000494:pharmacology
D000970:Antineoplastic Agents; D020719:Glucuronides; D018796:Immunoconjugates; D011355:Prodrugs; D005966:Glucuronidase; D002166:Camptothecin